A Phase 1 interventional study of Rosuvastatin and Pirtobrutinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received study intervention through oral administration as follows: * Day 1: 20 milligram (mg) rosuvastatin alone * Day 6: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib * Days 7 to 12: Once daily (QD) doses of 200 mg pirtobrutinib alone * Day 13: 20 mg rosuvastatin co-administered with 200 mg pirtobrutinib * Days 14 to 17: QD doses of 200 mg pirtobrutinib alone.
Drug: Rosuvastatin · Drug: Pirtobrutinib
Administered Orally.
Administered Orally.
Also known as: LY3527727
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Rosuvastatin
PK: Cmax of Rosuvastatin
Time frame: Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Rosuvastatin
PK: AUC(0-inf) of Rosuvastatin
Time frame: Day 1, Day 6 and Day 13: Predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 hours (h) post-dose.
| Milestone | Rosuvastatin + Pirtobrutinib |
|---|---|
| Started | 32 |
| Safety population day 1, day 6 and days 7-12 | 32 |
| Safety population day 13, days 14-17 | 31 |
| Completed | 28 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Adverse event | 1 |
PK: Cmax of Rosuvastatin
| nanograms per milliliter (ng/mL) | Rosuvastatin + Pirtobrutinib |
|---|---|
| Day 1 | 9.45 ± 56 |
| Day 6 | 23.0 ± 51 |
| Day 13 | 23.0 ± 49 |
PK: AUC(0-inf) of Rosuvastatin
| nanograms*hours per milliliter(ng*h/mL) | Rosuvastatin + Pirtobrutinib |
|---|---|
| Day 1 | 88.2 ± 44 |
| Day 6 | 189 ± 41 |
| Day 13 | 207 ± 40 |
Collected over Baseline to end of follow-up (up to 24 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20 mg Rosuvastatin (Day 1) | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| 20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 6) | 0/32 (0%) | 0/32 (0%) | 1/32 (3.1%) |
| 200 mg Pirtobrutinib QD (Days 7-12) | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| 20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 13) | 0/31 (0%) | 0/31 (0%) | 0/31 (0%) |
| 200 mg Pirtobrutinib QD (Days 14-17) | 0/31 (0%) | 0/31 (0%) | 1/31 (3.2%) |
| Event | 20 mg Rosuvastatin (Day 1) | 20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 6) | 200 mg Pirtobrutinib QD (Days 7-12) | 20 mg Rosuvastatin + 200 mg Pirtobrutinib (Day 13) | 200 mg Pirtobrutinib QD (Days 14-17) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/32 | 0/32 | 1/32 | 0/31 | 0/31 |
| PetechiaeSkin and subcutaneous tissue disorders | 0/32 | 1/32 | 3/32 | 0/31 | 1/31 |
All enrolled participants.
| Age, Continuous(years) | Rosuvastatin + Pirtobrutinib |
|---|---|
| Mean | 44.6 ± 10.6 |
| Sex: Female, Male(Participants) | Rosuvastatin + Pirtobrutinib |
|---|---|
| Female | 5 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | Rosuvastatin + Pirtobrutinib |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Rosuvastatin + Pirtobrutinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 15 |
| White | 15 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Rosuvastatin + Pirtobrutinib |
|---|---|
| United States | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2022 to primary completion in Apr 2022, 3 months.
Results were first posted in Sep 2024, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib